I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>United States</th>
</tr>
</thead>
</table>
| Applicant Eligibility Criteria | • The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.  
• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.  
• For projects offering continuing education credit, the requesting organization must be accredited. |

III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>October 7, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Atopic Dermatitis</td>
</tr>
</tbody>
</table>
| Background             | Atopic dermatitis (AD) is a chronic, relapsing, pruritic inflammatory skin disease that has an age-specific typical morphology and distribution. Diagnosis of AD, especially the moderate and severe forms, is not as straightforward. There are no biomarkers to confirm the diagnosis. Atopic Dermatitis can present differently depending on multiple factors including age, environmental exposures and ethnicity. Additionally, AD is associated with poorer quality of life. There are also significant psychosocial issues that affect patients. There are numerous co-morbidities seen in patients with AD that all allergists and other allergy practitioners should be familiar with in management of their patients.  
  Current therapies include supportive care, emollients, topical anti-inflammatories, and biologics. Targeted therapies are becoming more and more prevalent in AD. These therapies expand the allergist’s and other allergy practitioners’ toolkit and may enhance targeted/individualized medicine.  
The immunopathology of AD is complex and still emerging; however, recent research has led to many potential targets for therapeutics. Recent surveys of allergists/immunologists indicate that there is a significant knowledge gap in the understanding of these new targets and particularly the role of small molecules and biologics for moderate-to- |
severe AD. These therapies have the potential to advance the care of patients with AD. It is imperative for allergists and other allergy practitioners to understand the role of these targeted therapies in the treatment of moderate-to-severe AD.

Finally, it is imperative that allergists are aware of all emerging therapeutic options and educated in a way that allows them to provide best up-to-date care for patients with moderate-to-severe atopic dermatitis.

The American College of Allergy, Asthma, & Immunology, with the support of Pfizer, propose the development of a request for proposals (RFP) for a comprehensive educational intervention to improve the ability of allergy practitioners to manage moderate to severe atopic dermatitis specifically in their ability to:

a. Diagnose moderate-to-severe atopic dermatitis in different skin types and specifically skin of color.
b. Make informed selection of therapies available now and in the pipeline, while managing the safety of and duration of treatment with systemic agents.
c. Provide personalized care appropriate for differences in age and ethnicity.
d. Educate patients on their role in successful disease management.
e. Assess the guidelines around vaccination requirements with immunosuppressive therapies.

While the Program will be designed to fund educational interventions, it is the Parties’ expectation that an initial proof of concept for delivering improved outcomes to patients will be demonstrated upon completion of the grant effort.
General Area of Interest for this RFP:

Projects that will be considered for Pfizer support should focus on the development of a comprehensive and innovative educational intervention to improve the ability of allergy practitioners to manage moderate-to-severe atopic dermatitis, specifically in their ability to:

- Diagnose moderate to severe atopic dermatitis in different skin types
- Make informed selection of therapies
- Provide personalized care appropriate for differences in age and ethnicity
- Educate their patients on their role in successful disease management

**NOTE:** While the Program will be designed to fund education interventions, it is the expectation that an initial proof of concept for delivering improved outcomes to patients will be demonstrated upon completion of the grant term. Additionally, it is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:

For allergists, pediatric allergists, dermatologists, pediatric dermatologists, and advanced practice providers (NPs and PAs) who are involved in the care and treatment of patients with AD.

Expected Approximate Monetary Range of Grant Applications:

Individual projects requesting up to $300,000 will be considered. We anticipate funding up to 4 projects.

Key Dates:

- RFP release date: October 7, 2021
- Grant Application due date: October 28, 2021
  
  Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5).
- Anticipated Grant Award Notification Date: late November 2021
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: on or after January 1, 2022

How to Submit:

- Please go to [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type (e.g., knowledge, LOI, research full proposal, and QI full proposal). Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
  - For the question “What type of request are you submitting?” select
Response to a Request for Proposal (RFP)
- For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
- Select the following Competitive Grant Program Name: 2021 I&I L – Mod-Severe AD for Allergists
- Select the following Primary Area of Interest: Atopic Dermatitis

Requirements for submission:
- Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed by the committee.

Questions:
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Solis at Amanda.solis@pfizer.com with the subject line “Knowledge Gaps in AD for Allergists.”

Grant Agreements:
- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.

Review and Approval Process
- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:
- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.
## General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

### Goals and Objectives
- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

### Needs Assessment for the Project
- Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

### Target Audience
- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

### Project Design and Methods
- Describe the planned project, the educational approach, and the way the planned methods address the established need.

### Innovation
- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

### Evaluation and Outcomes
- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

### Dissemination Plan
- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
## Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

## Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

## Organization Detail

- Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.

## Budget Narrative

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.

- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.